Dasatinib

Catalog No.S1021 Synonyms: BMS-354825

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Cited by 202 Publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nat Immunol, 2018, 19(6):561-570

PubMed: 29777213 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Nat Med, 2017, 23(3):291-300

PubMed: 28191885 ( click the link to review the publication )

Nat Med, 2017, 23(12):1424-1435

PubMed: 29131160 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Cancer Cell, 2016, 29(4):563-573

PubMed: 27070703 ( click the link to review the publication )

Nat Genet, 2014, 46(2):166-70

PubMed: 24413734 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Am J Respir Crit Care Med, 2019, 101164/rccm201902-0451OC

PubMed: 31738079 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2556

PubMed: 31186408 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1515

PubMed: 30944303 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-2309

PubMed: 31857430 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(16):5038-5048

PubMed: 31182436 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.215939

PubMed: 31289206 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1104

PubMed: 31585938 ( click the link to review the publication )

Mol Syst Biol, 2019, 15(3):e8323

PubMed: 30858180 ( click the link to review the publication )

Cancer Res, 2019, 79(13):3306-3319

PubMed: 31101761 ( click the link to review the publication )

Theranostics, 2019, 9(7):1952-1964

PubMed: 31037149 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )
Thyroid, 2019, 29(3):395-404

PubMed: 30724135 ( click the link to review the publication )

Oncogene, 2019, 38(12):2135-2150

PubMed: 30459358 ( click the link to review the publication )

Stem Cell Reports, 2019, 10.1016/j.stemcr.2019.08.005

PubMed: 31522974 ( click the link to review the publication )

Br J Cancer, 2019, 121(7):567-577

PubMed: 31474759 ( click the link to review the publication )

J Clin Med, 2019, 8(8)

PubMed: 31382448 ( click the link to review the publication )

Cancer Discov, 2019, 9(6):756-777

PubMed: 30862724 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0449

PubMed: 31744897 ( click the link to review the publication )

J Physiol, 2019, 597(6):1627-1642

PubMed: 30488437 ( click the link to review the publication )

Mol Biol Cell, 2019, 30(9):1108-1117

PubMed: 30785867 ( click the link to review the publication )

Sci Rep, 2019, 9(1):4819

PubMed: 30894630 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7617

PubMed: 31110200 ( click the link to review the publication )

Sci Rep, 2019, 9(1):17171

PubMed: 31748572 ( click the link to review the publication )

Nanomaterials (Basel), 2019, 9(12)

PubMed: 31888247 ( click the link to review the publication )

J Proteome Res, 2019, 18(1):522-534

PubMed: 30540191 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 369(3):531-545

PubMed: 30898866 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):485

PubMed: 31118072 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2019, 9:80-86

PubMed: 30771616 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2019, 84(6):1241-1256

PubMed: 31541266 ( click the link to review the publication )

PLoS One, 2019, 14(2):e0212210

PubMed: 30779812 ( click the link to review the publication )

PLoS One, 2019, 14(2):e0212860

PubMed: 30794695 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(1):189-199

PubMed: 29741440 ( click the link to review the publication )

Environ Mol Mutagen, 2019, 60(6):513-533

PubMed: 30702769 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )
J Immunol Methods, 2019, 464:22-30

PubMed: 30347189 ( click the link to review the publication )

Oncotarget, 2019, 10(23):2237-2251

PubMed: 31040916 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Sci Transl Med, 2018, 10(427)

PubMed: 29437150 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1523

PubMed: 29670076 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):85

PubMed: 29925404 ( click the link to review the publication )

Oncogene, 2018, 37(16):2104-2121

PubMed: 29379163 ( click the link to review the publication )

Oncogene, 2018, 37(21):2837-2849

PubMed: 29511345 ( click the link to review the publication )

Cell Mol Life Sci, 2018, 75(22):4223-4234

PubMed: 29955905 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459283 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):183

PubMed: 30081903 ( click the link to review the publication )

EBioMedicine, 2018, 29:112-127

PubMed: 29433983 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30572654 ( click the link to review the publication )

Cell Commun Signal, 2018, 16(1):21

PubMed: 29776413 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(10):1556-1567

PubMed: 29903769 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(7)

PubMed: 30036966 ( click the link to review the publication )

Sci Rep, 2018, 8(1):5362

PubMed: 29599515 ( click the link to review the publication )

Food Chem Toxicol, 2018, 119:464-478

PubMed: 29097117 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Front Pharmacol, 2018, 9:403

PubMed: 29765318 ( click the link to review the publication )

Front Pharmacol, 2018, 9:1285

PubMed: 30473665 ( click the link to review the publication )

Int J Oncol, 2018, 52(6):2061-2068

PubMed: 29620253 ( click the link to review the publication )
Cytokine, 2018, 111:209-215

PubMed: 30176559 ( click the link to review the publication )

Cell Adh Migr, 2018, 12(3):286-298

PubMed: 28678601 ( click the link to review the publication )

Toxicol Lett, 2018, 296:39-47

PubMed: 30086328 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

FEBS Open Bio, 2018, 8(5):732-742

PubMed: 29744288 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncoscience, 2018, 5(1-2):21-38

PubMed: 29556515 ( click the link to review the publication )

Nature, 2018, 563(7730):265-269

PubMed: 30401838 ( click the link to review the publication )

Sci Transl Med, 2017, 9(374)

PubMed: 28123069 ( click the link to review the publication )

Sci Transl Med, 2017, 9(414)10

PubMed: 29093181 ( click the link to review the publication )

Blood, 2017, 129(11):e26-e37

PubMed: 28122742 ( click the link to review the publication )

Mol Cell, 2017, 66(5):635-647

PubMed: 28575659 ( click the link to review the publication )

Nat Commun, 2017, 8:14073

PubMed: 28102225 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(23):7360-7374

PubMed: 28939749 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):118

PubMed: 28606127 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2387-2398

PubMed: 28775147 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1729-1738

PubMed: 28619758 ( click the link to review the publication )

Neoplasia, 2017, 19(4):354-363

PubMed: 28319809 ( click the link to review the publication )

Toxicol Sci, 2017, 162(1):146-166

PubMed: 29106658 ( click the link to review the publication )

J Biol Chem, 2017, 292(35):14381-14390

PubMed: 28684419 ( click the link to review the publication )

Cancer Med, 2017, 6(4):809-818

PubMed: 28316141 ( click the link to review the publication )

Clin Res Hepatol Gastroenterol, 2017, 41(6):677-686

PubMed: 28578938 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:73-83

PubMed: 28123301 ( click the link to review the publication )
J Neurophysiol, 2017, 118(1):595-609

PubMed: 28446585 ( click the link to review the publication )

Eur J Haematol, 2017, 99(5):442-448

PubMed: 28881484 ( click the link to review the publication )

Arch Pharm Res, 2017, 40(2):197-203

PubMed: 27988882 ( click the link to review the publication )

Mol Vis, 2017, 23:823-831

PubMed: 29225458 ( click the link to review the publication )

Ther Drug Monit, 2017, 39(3):252-262

PubMed: 28490048 ( click the link to review the publication )

Oncotarget, 2017, 8(47):81794-81802

PubMed: 29137222 ( click the link to review the publication )

Oncotarget, 2017, 8(43):73871-73883

PubMed: 29088753 ( click the link to review the publication )

Nat Commun, 2016, 7:10060

PubMed: 26725982 ( click the link to review the publication )

Nat Commun, 2016, 7:11889

PubMed: 27297662 ( click the link to review the publication )

Nat Commun, 2016, 7:12428

PubMed: 27687249 ( click the link to review the publication )

Leukemia, 2016, 30(6):1273-81

PubMed: 26987906 ( click the link to review the publication )

Leukemia, 2016, 30(7):1493-501

PubMed: 27044711 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(51):E8228-E8237

PubMed: 27930322 ( click the link to review the publication )

Cancer Res, 2016, 76(12):3520-30

PubMed: 27197167 ( click the link to review the publication )

Int J Cancer, 2016, 139(10):2359-69

PubMed: 27434411 ( click the link to review the publication )

Cancer Lett, 2016, 376(1):188-96

PubMed: 26996299 ( click the link to review the publication )

Breast Cancer Res, 2016, 18(1):80

PubMed: 27495374 ( click the link to review the publication )

Development, 2016, 143(10):1674-87

PubMed: 26989177 ( click the link to review the publication )

J Infect Dis, 2016, 213(11):1767-76

PubMed: 26802142 ( click the link to review the publication )

Stem Cells Int, 2016, 2016:9601493

PubMed: 26788073 ( click the link to review the publication )

BMC Cancer, 2016, 16:229

PubMed: 26984511 ( click the link to review the publication )

Oncol Lett, 2016, 12(5):3598-3608

PubMed: 27900042 ( click the link to review the publication )

Assay Drug Dev Technol, 2016, 14(7):395-406

PubMed: 27552144 ( click the link to review the publication )

Oncotarget, 2016, 7(37):59236-59244

PubMed: 27494860 ( click the link to review the publication )
Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Sci Transl Med, 2015, 7(284):284ra57

PubMed: 25904741 ( click the link to review the publication )

Blood, 2015, 125(8):1282-91

PubMed: 25515960 ( click the link to review the publication )

Leukemia, 2015, 29(3):586-597

PubMed: 25134459 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.02.044

PubMed: 25737303 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1767

PubMed: 25996294 ( click the link to review the publication )

Radiother Oncol, 2015, 116(3):431-7

PubMed: 26320552 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(1):262-8

PubMed: ( click the link to review the publication )

Eur Neuropsychopharmacol, 2015, 25(8):1275-86

PubMed: 25983018 ( click the link to review the publication )

J Cell Sci, 2015, 128(2):251-65

PubMed: ( click the link to review the publication )

Eur Neuropsychopharm, 2015, 10.1016/j.euroneuro.2015.04.021

PubMed: ( click the link to review the publication )

Clin Immunol, 2015, 157(2):205-215

PubMed: 25728491 ( click the link to review the publication )

Neurotox Res, 2015, 27(4):384-98

PubMed: 25782580 ( click the link to review the publication )

Arch Biochem Biophys, 2015, 10.1016/j.taap.2015.03.018

PubMed: 25843419 ( click the link to review the publication )

PLoS One, 2015, 10(6):e0129663

PubMed: 26061184 ( click the link to review the publication )

Pulm Pharmacol Ther, 2015, 10.1016/j.pupt.2015.03.001

PubMed: 25843005 ( click the link to review the publication )

Leuk Res, 2015, 10.1016/j.leukres.2015.08.007

PubMed: 26346348 ( click the link to review the publication )

Mol Med Rep, 2015, 12(3):3249-3256

PubMed: 25975261 ( click the link to review the publication )

Int J Clin Exp Pathol, 2015, 8(7):7818-24

PubMed: 26339346 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: 25269544 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(4):557-62

PubMed: 25712742 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 6(14):12405-20

PubMed: 25915159 ( click the link to review the publication )

Blood, 2014, 123(21):3296-304

PubMed: 24723681 ( click the link to review the publication )
Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Leukemia, 2014, 28(10):2109-12

PubMed: 24919804 ( click the link to review the publication )

Cell Rep, 2014, 8(4):1037-48

PubMed: 25127139 ( click the link to review the publication )

Elife, 2014, 3:e02523

PubMed: 24844246 ( click the link to review the publication )

Cancer Lett, 2014, 344(1):90-100

PubMed: 24513268 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1023

PubMed: 24457967 ( click the link to review the publication )

Cell Death Dis, 2014, 6:e1595

PubMed: 25590805 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 14):3039-51

PubMed: 24928894 ( click the link to review the publication )

Int J Mol Sci, 2014, 15(4):5838-51

PubMed: 24714091 ( click the link to review the publication )

Exp Cell Res, 2014, 328(1):20-31

PubMed: 25128812 ( click the link to review the publication )

J Pharm Biomed Anal, 2014, 94:125-31

PubMed: 24561338 ( click the link to review the publication )

PLoS One, 2014, 9(9):e107367

PubMed: 25198091 ( click the link to review the publication )

PLoS One, 2014, 9(1):e85485

PubMed: 24427313 ( click the link to review the publication )

Mol Biosyst, 2014, 10.1039/C4MB00224E

PubMed: 25099472 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Leuk Lymphoma, 2014, 10.3109/10428194.2014.898759

PubMed: 24597981 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Head Neck, 2014, 36(3):375-84

PubMed: 23729178 ( click the link to review the publication )

Graefes Arch Clin Exp Ophthalmol, 2014, 10.1007/s00417-014-2674-7

PubMed: 24874745 ( click the link to review the publication )

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )

Oncoscience, 2014, 1(1):57-68

PubMed: 25593988 ( click the link to review the publication )

J Exp Med, 2013, 210(11):2205-21

PubMed: 24127489 ( click the link to review the publication )

J Exp Med, 2013, 210(12):2569-82

PubMed: 24190431 ( click the link to review the publication )
Clin Cancer Res, 2013, 19(18):5053-67

PubMed: 23900136 ( click the link to review the publication )

PLoS Biol, 2013, 11(3):e1001515

PubMed: 23526884 ( click the link to review the publication )

Cancer Lett, 2013, 340(1):43-50

PubMed: 23811285 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(4):518-26

PubMed: 23582185 ( click the link to review the publication )

Neoplasia, 2013, 15(11):1272-81

PubMed: 24339739 ( click the link to review the publication )

J Thorac Cardiovasc Surg, 2013, 145(2):531-8

PubMed: 23142123 ( click the link to review the publication )

J Neurochem, 2013, 12(12):2864-73

PubMed: 24130049 ( click the link to review the publication )

J Biol Chem, 2013, 288(8):5553-61

PubMed: 23303179 ( click the link to review the publication )

Int J Oncol, 2013, 43(6):2064-72

PubMed: 24126464 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 72(1):35-44

PubMed: 23712327 ( click the link to review the publication )

Pharmgenomics Pers Med, 2013, 6:63-72

PubMed: 24019750 ( click the link to review the publication )

Sci Rep, 2013, 3:2100

PubMed: 23812503 ( click the link to review the publication )

Sci Transl Med, 2012, 4(136):136ra70

PubMed: 22649091 ( click the link to review the publication )

Blood, 2012, 119(21):4981-91

PubMed: 22411867 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(1):127-39

PubMed: 22090359 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(17):6584-10

PubMed: 22492965 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Br J Haematol, 2012, 157(4):510-4

PubMed: 22313359 ( click the link to review the publication )

J Virol, 2012, 86(16):8765-72

PubMed: 22696643 ( click the link to review the publication )

Angiogenesis, 2012, 15(1):33-45

PubMed: 22203239 ( click the link to review the publication )

Cancer Immunol Immun, 2012, 61(2):193-202

PubMed: 21874302 ( click the link to review the publication )

Invest New Drugs, 2012, 30(1):417-22

PubMed: 20953816 ( click the link to review the publication )

Stem Cells Dev, 2012, 21(16):2939-48

PubMed: 22642671 ( click the link to review the publication )

Hematol Oncol, 2012, 31(3):156-63

PubMed: 23108877 ( click the link to review the publication )
PLoS One, 2012, 7(7):e40853

PubMed: 22815843 ( click the link to review the publication )

J Biomol Screen, 2012, 18(4):388-99

PubMed: 23134735 ( click the link to review the publication )

J Liq Chromatogr R T, 2012, 2503-2510

PubMed: ( click the link to review the publication )

Cell Res, 2011, 21(7):1080-7

PubMed: 21423276 ( click the link to review the publication )

J Mol Biol, 2011, 411(2):474-85

PubMed: 21699901 ( click the link to review the publication )

J Virol, 2011, 85(5):2296-303

PubMed: 21177802 ( click the link to review the publication )

Cancer Prev Res , 2011, 4(8):1222-32

PubMed: 21546539 ( click the link to review the publication )

J Biol Chem, 2011, 286(16):13846-51

PubMed: 21343293 ( click the link to review the publication )

Exp Hematol, 2011, 39(8):859-65.e2

PubMed: 21689725 ( click the link to review the publication )

PLoS One, 2010, 5(11):e14143

PubMed: 21152443 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Targets

Abl ^[1] (Cell-free assay)	Src ^[1] (Cell-free assay)	c-Kit (D816V) ^[2] (Cell-free assay)	c-Kit (wt) ^[2] (Cell-free assay)
0.6 nM	0.8 nM	37 nM	79 nM

In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. ^[1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. ^[3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
M07ep210	MmDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2WzdVczKGh?	MWXEUXNQ	MX\JR\|UxRTBwMECwNFch\|ryP	M{PzSVE4QTV4MEiw
K562	MljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUTadplWPzJiaB?=	NVThflVHTE2VTx?=	M3TtcmlEPTB;MD6wNFEh\|ryP	NXPleoxzOTd7NU[wPFA>
M07e	NHjm[mFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUKxW5VnPzJiaB?=	NUfFeXlrTE2VTx?=	MXPJR\|UxRTBwMECxNkDPxE1?	M1rqblE4QTV4MEiw
ALL3	NXLY[YRLS3m2b4TvfIlkKEG\|c3H5	M{XENVAvOc7:TR?=	NVXkZXJUPzJiaB?=	Mn3GSG1UVw>?	M4DWTmlEPTB;MD6wNFA1KM7:TR?=	NH;uNpIyQTh6OUW0NC=>
CML	M4W2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlzsNlAhdWmw	NH\JfmRFVVOR	NH;xfJNKSzVyPUCuNFAyKM7:TR?=	NHvBRXEyQTJzOUCxOi=>
BA/F3	NIj4WZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIPGPGM4OiCq	MlTMSG1UVw>?	NFzVS4hKSzVyPU[uOVg6KM7:TR?=	MoTxNlMxQDh4NES=
BA/F3	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXe3NkBp	MV\EUXNQ	NUP5N4FGUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBOOzVzVDDteZRidnRid3n0bEBKSzVyIH;mJFAvODByOEROwG0>	MWOyN\|A5QDZ2NB?=
BA/F3	NVHLR3o2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2raSlczKGh?	MkLlSG1UVw>?	MVnJcoR2[2W\|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzD3bYxlKHS7cHWgRoNzNUGkbDD3bZRpKEmFNUCgc4YhOC5yMES1{txO	MXKyN\|A5QDZ2NB?=
BA/F3	NEXlRpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1j6elczKGh?	NWHCWoZITE2VTx?=	NUPXeohbUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBVOzF3STDteZRidnRid3n0bEBKSzVyIH;mJFEvPzF2zszN	M1zwSFI{ODh6NkS0
BA/F3	NIP6N2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlH0O\|IhcA>?	MYXEUXNQ	MVzJcoR2[2W\|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBHPDh4UzDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECwPe69VQ>?	M1L1OVI{OzBzN{Cz
BA/F3	NGTXO5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVv2W3NPPzJiaB?=	NXHmfYk6TE2VTx?=	NXPhSWd4UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRUK1OWshdXW2YX70JIF{e2W\|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOzMQvF2=	MXuyN\|MxOTdyMx?=
BA/F3	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Ml3xO\|IhcA>?	MnPESG1UVw>?	NFz3SI9KdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCJMkWwSUBufXSjboSgZZN{\XO\|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR\|UxKG:oIECuNFA2Oc7:TR?=	Mm[3NlM{ODF5MEO=
BA/F3	NITnfodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoXTO\|IhcA>?	NEj6T4ZFVVOR	NUn4OnZ{UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiUUK1NmghdXW2YX70JIF{e2W\|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxQM7:TR?=	NGDi[pUzOzNyMUewNy=>
BA/F3	NYPOdWlbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWK3NkBp	M1\3d2ROW09?	M2jHZ2lv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV\|NUnWJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFE{\|ryP	NEPkcZMzOzNyMUewNy=>
BA/F3	NUf5ZnZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXO3NkBp	MojySG1UVw>?	MWrJcoR2[2W\|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKFUj3BRmwh[XO\|ZYPz[YQh[XNiZ4Lve5RpKEmwaHnibZRqd25id3n0bEBKSzVyIH;mJFAvODBzOd88US=>	NGDXTFkzOzNyMUewNy=>
BA/F3	NH3CfHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnnyO\|IhcA>?	M1TzVGROW09?	NXTDW2NEUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiWUK1N2ghdXW2YX70JIF{e2W\|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOjQQvF2=	NXS1Nm1bOjN\|MEG3NFM>
BA/F3	NWD4RW44T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXHQe3V{PzJiaB?=	NFvqbYlFVVOR	M3vkW2lv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFR\|MUXJJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMz62{txO	MnjTNlM{ODF5MEO=
BA/F3	MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVy3Xpk3PzJiaB?=	MofPSG1UVw>?	MmPkTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghUW6qaXLpeIlwdiC5aYToJGlEPTBib3[gNk42\|ryP	NWq1XZl6OjN\|MEG3NFM>
T cell	NVv0PHdKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYe3NkBp	MWTEUXNQ	MoTiTY5pcWKrdIOgZY51cSCFREOtJIFv\CCjboTpJGNFOjhvaX7keYNm\CCWIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5yMEROwG0>	MWSxO\|E2PDVzMh?=
WiDr	NEHkeZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXvvT3R6PzJiaB?=	Mkm4SG1UVw>?	M2HVe2lEPTB;MD6wOVIh\|ryP	NGG1RmcyPTZzNUWxNi=>
PC3	M1\TdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3PZR\|czKGh?	MY\EUXNQ	NH7Yc3hKSzVyPUCuNFA6PCEQvF2=	M2HHSVE2PjF3NUGy
MDA-MB-231	MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIS5VnA4OiCq	NGXHfWdFVVOR	MkXMTWM2OD1yLkCxNkDPxE1?	MmHONVU3OTV3MUK=
Hs578T	M3e2V2N6fG:2b4jpZ{BCe3OjeR?=		MUC3NkBp	MWHEUXNQ	NXLJTZdKT0l3ME2wMlA{KM7:TR?=	M1PPdVI1ODF3M{K3
HMEC	MmPZR5l1d3SxeHnjJGF{e2G7		NF3ZXXE4OiCq	NVq3T3VvTE2VTx?=	NG\2WphIUTVyPUGuPEDPxE1?	NWLGfmhJOjRyMUWzNlc>
DU145	MXjDfZRwfG:6aXOgRZN{[Xl?		M4nDdFczKGh?	NGH2OIVFVVOR	MVrHTVUxRTBwMU[g{txO	NFXOTG0zPDBzNUOyOy=>
U251	MX3DfZRwfG:6aXOgRZN{[Xl?		M2q4WlczKGh?	NIXWSo5FVVOR	M1rzZWdKPTB;Mj64NUDPxE1?	NUjqVJNHOjRyMUWzNlc>
NCI60	NYfo[nV[S3m2b4TvfIlkKEG\|c3H5		MoDkO\|IhcA>?	NFfHXWFFVVOR	MXjHTVUxRTVwNzFOwG0>	MljSNlQxOTV\|Mke=
MALME-3M	MnrnR5l1d3SxeHnjJGF{e2G7		NEnuN4o4OiCq	M{e4dWROW09?	MmS5S2k2OD14Lk[xJO69VQ>?	NWTVTlhMOjRyMUWzNlc>
KM12	MUPDfZRwfG:6aXOgRZN{[Xl?		NWnXZmxKPzJiaB?=	NUHWZmR1TE2VTx?=	MU\HTVUxRTdwNESg{txO	MmDoNlQxOTV\|Mke=
SW620	NG\mfoZEgXSxdH;4bYMhSXO\|YYm=		M3nuW\|czKGh?	M3TyNGROW09?	NXXLeo9GT0l3ME24MlQ{KM7:TR?=	M{PpWVI1ODF3M{K3
RXF 393NL	M1HqfGN6fG:2b4jpZ{BCe3OjeR?=		NWHVXldnPCCmYYnz	NXTQUlhqTE2VTx?=	NF64dlBKSzVyPUCuNFIyPyEQvF2=	MVuyN\|I2OzB5NB?=
LXFA 983L	NWDKZplZS3m2b4TvfIlkKEG\|c3H5		NIe1OpU1KGSjeYO=	MonkSG1UVw>?	NIPlPZpKSzVyPUCuNFU3PSEQvF2=	M{DicFI{OjV\|MEe0
PRXF DU145	MlvyR5l1d3SxeHnjJGF{e2G7		MXK0JIRigXN?	NYCyblZZTE2VTx?=	MVvJR\|UxRTBwME[yN{DPxE1?	MknyNlMzPTNyN{S=
PAXF 1657L	NUXMWG9iS3m2b4TvfIlkKEG\|c3H5		MU[0JIRigXN?	NWPpPJBuTE2VTx?=	NVPRfpl5UUN3ME2wMlEzOSEQvF2=	NXjaVGhHOjN{NUOwO\|Q>
CXF 1103L	M2H2UWN6fG:2b4jpZ{BCe3OjeR?=		NWrvdnlCPCCmYYnz	MljMSG1UVw>?	NUnXdGd6UUN3ME20MlM3KM7:TR?=	MmLwNlMzPTNyN{S=
GXF251L	MUDDfZRwfG:6aXOgRZN{[Xl?		MWm0JIRigXN?	M1LrV2ROW09?	MWTJR\|UxRTJwMkWg{txO	MVWyN\|I2OzB5NB?=
NCI-H23	NE\UfnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoH6O\|IhcA>?	M{j0S2ROW09?	NYnVdW1nUUN3ME2yMlI4KM7:TR?=	MlP6NlM2OjFyMkC=
HCT116	NX3wPZZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnPPO\|IhcA>?	M2LUWmROW09?	NXzIWFNZUUN3ME2yMlMh\|ryP	MnTINlM2OjFyMkC=
MCF7	NIWwWYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlvSO\|IhcA>?	NV3iW3FCTE2VTx?=	Mmr5TWM2OD1{LkW3JO69VQ>?	M1\VR\|I{PTJzMEKw
NCI-H460	Mle4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWLudHJGPzJiaB?=	NUKzZm5QTE2VTx?=	MXzJR\|UxRThwOUmg{txO	MlvJNlM2OjFyMkC=
DLD1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1\3[FczKGh?	NF34XlZFVVOR	MVjJR\|UxRTRwNjFOwG0>	M{nLR\|I{PTZ5OU[w
NCI-H661	MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnHFO\|IhcA>?	NUL1PZR4TE2VTx?=	NUPsbGhqUUN3ME23Mlgh\|ryP	MVSyN\|U3Pzl4MB?=
A549	M37WfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MV[3NkBp	MYnEUXNQ	MlvrTWM2OD16LkKg{txO	MknJNlM2Pjd7NkC=
U937	Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIS2VHY4OiCq	MmnySG1UVw>?	NG\zXnJKSzVyPUGyMlIh\|ryP	NH[0VZczOzV4N{m2NC=>
HEK293	NFnBXWlHfW6ldHnvckBCe3OjeR?=	M3;WflExyqEQvF2=		M1HrdGROW09?	MojkTY5lfWOnczDibY5lcW6pIHHm[olvcXS7IITvJIh2dWGwIH\1cIwudGWwZ4ToJGhqey22YXfn[YQhVXm2MTDrbY5ie2ViZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyC5aYToJGlEPTBib3[gNE4xPjQQvF2=	NHf5RoozOjd5ME[xNC=>
HUVEC	NF\KdZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV:wMlE2yqEQvF2=	Mn7pO\|IhcA>?	NV\pNpR4TE2VTx?=	MorPTY5lfWOnczDhcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGSyClbz3jeYx1fXKnZDD3bZRpKH[jc3P1cIFzKHOvb3;0bEBufXOlbHWgZ4VtdHNiYYPz[ZN{\WRiYYOgTY5pcWKrdHnvckBw\iClZXzsJIdzd3e2aDDheEAxNjF3IIXN	NH;vNZczOjh3M{m5Ny=>
HUVEC	MYPGeY5kfGmxbjDBd5NigQ>?	NEjDfoMyPcLizszN	NF7Rd2U4OiCq	M1zYU2ROW09?	MX7JcoR2[2W\|IHHueIlidmerb3flcolkKGGldHn2bZR6KGmwIFjVWmVEKGOxLXP1cJR2emWmIIfpeIghfmG\|Y4XsZZIhe22xb4ToJI12e2OuZTDj[YxteyCjc4Pld5Nm\CCjczDJcohq[mm2aX;uJI9nKG6ndIfvdosh\m:{bXH0bY9vKGG2IEGuPEB1dyBzNTD1US=>	NYfFXZBVOjJ6NUO5PVM>
Plasmodium falciparum	M3;ocmZ2dmO2aX;uJGF{e2G7	NFfubnIyOMLizszN	NXfnd3dNOTVibXnu	NXTvNFMzTE2VTx?=	NIiweY5KdmirYnn0d{BRdGG\|bX;kbZVuKG[jbHPpdIFzfW1icILvcIln\XKjdHnvckBjgSCrbnjpZol1cW6pIITo[UBHfW6ldHnvckBw\iCSZlPEVGsyKHC{b4TlbY4hf2m2aDDJR\|UxKG:oIEGuNVfPxE1?	NV2zUoFTOjR3NUCzN\|A>
PC3	M1nH[GZ2dmO2aX;uJGF{e2G7	Mn3WNE4yKM7:TR?=	M4PZRlUhcA>?	NF[4cFhFVVOR	NX7MZ254UW6qaXLpeJMhcHWvYX6gVGM{KGOnbHygZYRp\XOrb36gZZQhOTByIH7N	M1nISlE6PDZ{OUe1
DU145	MXHGeY5kfGmxbjDBd5NigQ>?	NHixVFQxNjFizszN	NVLkT2RvPSCq	NF;YNIRFVVOR	NWDNU2ppUW6qaXLpeJMhcHWvYX6gSHUyPDViY3XscEBi\Ginc3nvckBifCBzMECgcm0>	NEHz[nAyQTR4Mkm3OS=>
PC3	M{jBXGtqdmG\|ZTDBd5NigQ>?	NF[5[40xNjFizszN	NV7lPZBIPSCq	M2fVPGROW09?	Mln2TY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJHNz[yC\NEG2JIxmfmWuIHH0JFExOCCwTR?=	M2XDXFE6PDZ{OUe1
DU145	MWTLbY5ie2ViQYPzZZk>	M{XrZlAvOSEQvF2=	MlvsOUBp	MlLaSG1UVw>?	M2LvO2lvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKFO{YzDZOFE3KGyndnXsJIF1KDFyMDDuUS=>	NGHuNWYyQTR4Mkm3OS=>
PC3	M2fjWWtqdmG\|ZTDBd5NigQ>?	M2W5[\|AvOSEQvF2=	NHLTZXQ2KGh?	MnfhSG1UVw>?	M13Fc2lvcGmkaYTzJINUemNiaX6gbJVu[W5iUFOzJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBHSUtiWUW3Ok9[PTd5IHzleoVtKGG2IEGwNEBvVQ>?	NHjw[2syQTR4Mkm3OS=>
DU145	MVjLbY5ie2ViQYPzZZk>	M{e0[\|AvOSEQvF2=	NG\nRVE2KGh?	MXnEUXNQ	MXfJcohq[mm2czDjV5JkKGmwIHj1cYFvKESXMUS1JINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBHSUtiWUW3Ok9[PTd5IHzleoVtKGG2IEGwNEBvVQ>?	NFroXIIyQTR4Mkm3OS=>
Huh7	NUTobJFDSW62aY\pdoFtKEG\|c3H5	Mn7mNk42KM7:TR?=	M{XMVFQh\GG7cx?=	MXjEUXNQ	NEfRRoFKdmirYnn0d{B3cXKjbDDzdJJm[WRiaX6gSIVv\3WnII\pdpV{NWmwZnXjeIVlKGi3bXHuJGh2cDdiY3XscJMh[XO\|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJI9nKH[rcnHsJIVvfmWub4DlJJBzd3SnaX6ge4l1cGmwIIDldolvfWOuZXHyJJJm\2mxbjDheEAzNjVidV2=	NF7EVokyPzN4ME[3Oi=>
C6/36	M{PHUGFvfGm4aYLhcEBCe3OjeR?=	MV[yMlUh\|ryP	MkDaOEBl[Xm\|	NUfiTG5lTE2VTx?=	NYLyPVlyUW6qaXLpeJMhfmm{YXygd5Bz\WGmIHnuJGRmdme3ZTD2bZJ2ey2rbn\lZ5Rm\CCjc3nhckB1cWencjDtc5NyfWm2bzDDOk8{PiClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TR?=	M{LrZ\|E4OzZyNke2
U937	MYHGeY5kfGmxbjDBd5NigQ>?	Mlf0NUDPxE1?	NXPjRVBUOSCq	Mn;wSG1UVw>?	NEj1NFdT\WS3Y3XzJIJie2GuIGTOSoFteGijIILlcIVie2ViaX6gbJVu[W5iVUmzO{Bk\Wyucx?=	NEPEdoEyPzZ6NEC5PS=>
U937	MVnGeY5kfGmxbjDBd5NigQ>?	NIexeVgyKM7:TR?=	NVT4OmN6OSCq	NEDXV3hFVVOR	MonUVoVlfWOnczDMVHMucW6mdXPl[EBVVk[jbIDoZUBz\WynYYPlJIlvKGi3bXHuJHU6OzdiY3XscJM>	MVmxO\|Y5PDB7OR?=
murine mast cell	Mnj5SpVv[3Srb36gRZN{[Xl?	NV3NV2M6OSEQvF2=	M{nCflI1KGh?	MlPLSG1UVw>?	M33qN2lvcGmkaYTzJIFvfGmpZX6tbY5lfWOnZDDJUFYhe2WlcnX0bY9vKGmwIFnnSUBxemmvZXSgcY92e2VibXHzeEBk\WyuczDheEAyKHWP	NXrwRmJJOTd4OESwPVk>
BV-173	MoPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mlr5TWM2OD1yLkCwNFAxODFyOTFOwG0>	NYX5b3JPW0GQR1XS
K-562	NX7yenBsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUK4fYg6UUN3ME2wMlAxODByMEK2OkDPxE1?	M4i4[XNCVkeHUh?=
BL-70	M3nPXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUmze3E5UUN3ME2wMlAxODByMEiyNkDPxE1?	NVTHNnRVW0GQR1XS
EM-2	M17LTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTBwMECwNFAyODhizszN	MoHNV2FPT0WU
LAMA-84	Ml72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jzcmlEPTB;MD6wNFAxODN{MTFOwG0>	NYjpe2YzW0GQR1XS
MEG-01	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX35S4p7UUN3ME2wMlAxODByOUig{txO	MV\TRW5ITVJ?
EoL-1-cell	NWXVZ3lQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTBwMECwNFE{OSEQvF2=	MV;TRW5ITVJ?
CTV-1	NV;TXYo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmizTWM2OD1yLkCwNFA1ODRizszN	M1X6PXNCVkeHUh?=
TE-15	NUnOWWZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfZTWM2OD1yLkCwOVg6KM7:TR?=	NVniWGxIW0GQR1XS
NOS-1	MofpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrWO5dKSzVyPUCuNFA3OTNizszN	Mn3hV2FPT0WU
D-336MG	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2nq[mlEPTB;MD6wNFY{KM7:TR?=	MUPTRW5ITVJ?
LB1047-RCC	NXf4U5FMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HBdmlEPTB;MD6wNFk5QSEQvF2=	MojhV2FPT0WU
LB996-RCC	M4PnR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHfsTVVKSzVyPUCuNFA6QTFizszN	NHLae2NUSU6JRWK=
SW982	NH2xcHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLRTWM2OD1yLkCxNVE2KM7:TR?=	NVjnZVJsW0GQR1XS
TK10	M{L4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnre2hKSzVyPUCuNFEyPzRizszN	NGDDWpJUSU6JRWK=
A704	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7oTWM2OD1yLkCxOFkyKM7:TR?=	NWDYcYlTW0GQR1XS
TE-8	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGHORmRKSzVyPUCuNFE2PzZizszN	NFHSeZZUSU6JRWK=
DOHH-2	NHn0d3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGTFV\|NKSzVyPUCuNFE4OTlizszN	NUm4dohIW0GQR1XS
HOP-62	M3zqS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3LSIRXUUN3ME2wMlAyQDN2IN88US=>	NILv[mdUSU6JRWK=
TE-12	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{H2OGlEPTB;MD6wNVg3OSEQvF2=	NX7DZo1uW0GQR1XS
KGN	M36xTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLFdlF{UUN3ME2wMlAyQTR{IN88US=>	MVvTRW5ITVJ?
NCI-H1648	NIDQOndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrjZ5VUUUN3ME2wMlAzODFzIN88US=>	NEmxdHZUSU6JRWK=
OS-RC-2	NWLFSWhUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\VTWlEPTB;MD6wNlA{KM7:TR?=	NGjE[HNUSU6JRWK=
GB-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVn3VnRTUUN3ME2wMlAzOTV5IN88US=>	NELacVRUSU6JRWK=
RXF393	M1TpXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLTS4NKSzVyPUCuNFI{PTdizszN	NWTmfFNKW0GQR1XS
LC-2-ad	M3HWfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7BTYVMUUN3ME2wMlAzPTh4IN88US=>	NI[xV2RUSU6JRWK=
KS-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjxOYNKSzVyPUCuNFI4OyEQvF2=	MmnJV2FPT0WU
ETK-1	M2H3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTBwMEK4N\|Ih\|ryP	MUTTRW5ITVJ?
SW954	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3XvXGlEPTB;MD6wNlkzPyEQvF2=	MoHLV2FPT0WU
Becker	Ml:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1;ORWlEPTB;MD6wN\|AxOyEQvF2=	NWiyOFFpW0GQR1XS
MZ1-PC	NFvEOXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLwfoRKSzVyPUCuNFMyOTlizszN	M3XjUHNCVkeHUh?=
ES6	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGD2Xm9KSzVyPUCuNFMyQTNizszN	MUnTRW5ITVJ?
KURAMOCHI	NX3iN2tbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3nZbmlEPTB;MD6wN\|Q5PyEQvF2=	NELnVoJUSU6JRWK=
CGTH-W-1	NYLtTZozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XlUGlEPTB;MD6wN\|U1QCEQvF2=	MmC5V2FPT0WU
VA-ES-BJ	NGTWV4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTBwMEO5NFIh\|ryP	NIXpUHpUSU6JRWK=
LXF-289	NIK1VGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIHzXVNKSzVyPUCuNFM6PTZizszN	NFPM[HJUSU6JRWK=
MPP-89	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17TdGlEPTB;MD6wOFA1QSEQvF2=	M1HQU3NCVkeHUh?=
SW872	NUHmPJJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFnKe5BKSzVyPUCuNFQyPjFizszN	M4nsU3NCVkeHUh?=
SNB75	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fvcWlEPTB;MD6wOFQ{PSEQvF2=	M4n0R3NCVkeHUh?=
PSN1	NFzwO2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEPubmNKSzVyPUCuNFQ1PzRizszN	MV;TRW5ITVJ?
LB831-BLC	M3jkTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYK2OYtTUUN3ME2wMlA1PjB7IN88US=>	NU\teZR1W0GQR1XS
MFH-ino	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkWzTWM2OD1yLkC0O\|I1KM7:TR?=	NX3ue5ptW0GQR1XS
TGBC24TKB	MlLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTBwMES3OlEh\|ryP	MXjTRW5ITVJ?
A388	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUOxW4RnUUN3ME2wMlA2ODl3IN88US=>	MXjTRW5ITVJ?
BB30-HNC	NVLocYtJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NETiZYdKSzVyPUCuNFU1OzdizszN	MkXhV2FPT0WU
GI-ME-N	NFPiVIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjJTWM2OD1yLkC2NVE5KM7:TR?=	MXXTRW5ITVJ?
TGBC1TKB	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHmTWM2OD1yLkC2NVY1KM7:TR?=	MoTyV2FPT0WU
TE-10	M1PERmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnvETWM2OD1yLkC2N\|U4KM7:TR?=	MYHTRW5ITVJ?
A498	M3ziXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTBwMEeyPFQh\|ryP	MYfTRW5ITVJ?
TE-11	MkTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfWUW9KSzVyPUCuNFc5PThizszN	M4K2fHNCVkeHUh?=
BB65-RCC	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEn0bpFKSzVyPUCuNFgzOjdizszN	MofRV2FPT0WU
C2BBe1	Mlr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUPBO2xDUUN3ME2wMlA5OzB6IN88US=>	NV3Wd5dtW0GQR1XS
NCI-H747	NXPvW5ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUH2[odVUUN3ME2wMlA5OzZ{IN88US=>	NF\ZUYFUSU6JRWK=
IST-MES1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPvfZBLUUN3ME2wMlA5PTV{IN88US=>	MmTZV2FPT0WU
KALS-1	M3LOTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWrqRnd1UUN3ME2wMlA6PDlizszN	M4W1XXNCVkeHUh?=
GCIY	NGXUVZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTBwMEm2OVYh\|ryP	MkjlV2FPT0WU
RL95-2	NHzRb5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXITWM2OD1yLkGwN\|gh\|ryP	Mn3GV2FPT0WU
TE-1	NXrQOHl5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XQcmlEPTB;MD6xNFU1KM7:TR?=	MUjTRW5ITVJ?
NCI-H1355	MoHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;odGlEPTB;MD6xNVAzQCEQvF2=	Ml3rV2FPT0WU
SW962	NWm4WGYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2rr[GlEPTB;MD6xNVI6OiEQvF2=	MYLTRW5ITVJ?
KLE	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17sdmlEPTB;MD6xNVMyPyEQvF2=	NGK0b5lUSU6JRWK=
MC116	M2DIR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTBwMUG0NUDPxE1?	NYTaOnU4W0GQR1XS
NMC-G1	M{XvOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnflTWM2OD1yLkGxOlA3KM7:TR?=	MV3TRW5ITVJ?
KU812	MnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnr[WVKSzVyPUCuNVE5QDNizszN	MXHTRW5ITVJ?
COLO-829	Mkj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NInYe5RKSzVyPUCuNVIzOTNizszN	MXXTRW5ITVJ?
NTERA-S-cl-D1	Mnn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFf2Ro9KSzVyPUCuNVIzQDNizszN	NV\vTmRGW0GQR1XS
IST-MEL1	NYG1c4kxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mne0TWM2OD1yLkGzOFUh\|ryP	NWfEeZpZW0GQR1XS
MLMA	M1Tnbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\3RWlEPTB;MD6xOFA{OiEQvF2=	NEDWTWVUSU6JRWK=
LS-123	NFXMWldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnWwTWM2OD1yLkG0NFY1KM7:TR?=	NH3lblZUSU6JRWK=
LB2518-MEL	M2fVcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTBwMUSxOlIh\|ryP	NELUenlUSU6JRWK=
NB69	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVH6PIVyUUN3ME2wMlE1PDN4IN88US=>	M4i0XHNCVkeHUh?=
8-MG-BA	NWfZNGNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2HK[2lEPTB;MD6xOVQ2QCEQvF2=	NWj5OnpYW0GQR1XS
K5	MnOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn\YTWM2OD1yLkG2OFg6KM7:TR?=	M2S4eHNCVkeHUh?=
KINGS-1	Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEn4dmNKSzVyPUCuNVY3PjZizszN	M1\Tb3NCVkeHUh?=
SF268	MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1mwN2lEPTB;MD6xO\|QxPCEQvF2=	MlyxV2FPT0WU
PF-382	MoTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTBwMUe2O\|gh\|ryP	NGXqe4ZUSU6JRWK=
SH-4	M1HBZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnIc4pKSzVyPUCuNVg1OTNizszN	NXrt[3dSW0GQR1XS
NALM-6	NHPaboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DCZWlEPTB;MD6xPVI6PSEQvF2=	NIrCN\|hUSU6JRWK=
CP66-MEL	M1\VWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTBwMUm1N\|Eh\|ryP	NXLNRWRsW0GQR1XS
697	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIrm[2hKSzVyPUCuNVk6QDdizszN	MnPZV2FPT0WU
CP67-MEL	NET2N2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3PDVWlEPTB;MD6yNFQ5QCEQvF2=	NX[1OHFOW0GQR1XS
DSH1	NHjQSWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfWTWM2OD1yLkK0NFAyKM7:TR?=	M4rkdXNCVkeHUh?=
HCE-4	MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;iS4pKSzVyPUCuNlY1OzlizszN	NXzkNFJLW0GQR1XS
MZ2-MEL	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XWRWlEPTB;MD6yPFU{PyEQvF2=	MV7TRW5ITVJ?
BL-41	NG\1OXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrwTWM2OD1yLkK5NVI{KM7:TR?=	NHTYXmNUSU6JRWK=
HUTU-80	MmPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;tTWM2OD1yLkOxOFIh\|ryP	MV\TRW5ITVJ?
LOXIMVI	NV;aXWI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTBwM{G1NFMh\|ryP	Mmm0V2FPT0WU
no-10	M1WxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTxfWtIUUN3ME2wMlMyQTNzIN88US=>	NVHseVB5W0GQR1XS
KARPAS-422	NFLGSJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTaTWM2OD1yLkOzPVk4KM7:TR?=	MmHDV2FPT0WU
SW684	Mn3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFGyRnlKSzVyPUCuN\|Q6QCEQvF2=	NXPhc2l{W0GQR1XS
SF126	MmnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHPiTWJKSzVyPUCuN\|U1OSEQvF2=	NWLHT5hsW0GQR1XS
D-263MG	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTBwM{[yNlQh\|ryP	MmHGV2FPT0WU
OVCAR-4	NGTx[49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTBwM{e0N\|Mh\|ryP	MoO4V2FPT0WU
BB49-HNC	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4HsWWlEPTB;MD6zPFU6QSEQvF2=	MX\TRW5ITVJ?
ONS-76	NFrRdW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITTPVhKSzVyPUCuOFI6PTFizszN	MVLTRW5ITVJ?
MZ7-mel	MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvvd2Z4UUN3ME2wMlQ4QTFzIN88US=>	NV\He3lsW0GQR1XS
RCC10RGB	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXIflE6UUN3ME2wMlQ6OTFizszN	M2j1d3NCVkeHUh?=
BOKU	MofMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPGTWM2OD1yLkS5NVM{KM7:TR?=	M2nDWnNCVkeHUh?=
no-11	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTBwNUCyNlgh\|ryP	M4r4TnNCVkeHUh?=
IST-SL2	M{[xN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTBwNUCzNFIh\|ryP	M2O1WnNCVkeHUh?=
RKO	NUPRcFZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTBwNUK5OlYh\|ryP	MVLTRW5ITVJ?
HT-144	MkjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVi0TGoxUUN3ME2wMlU{PjB7IN88US=>	MnXpV2FPT0WU
NCI-H446	NYrHPYtoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{H3UGlEPTB;MD62Nlc3KM7:TR?=	Ml;lV2FPT0WU
QIMR-WIL	MnPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4W4cmlEPTB;MD63NFYzQSEQvF2=	NY\2THY6W0GQR1XS
MHH-PREB-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{mxVWlEPTB;MD63OFQ3QSEQvF2=	NGjuO5FUSU6JRWK=
EW-16	NYDTbYpmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MonFTWM2OD1yLke2NVc5KM7:TR?=	NED6[XBUSU6JRWK=
EW-24	NFvESIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlH3TWM2OD1yLke4NVY2KM7:TR?=	NITqb3BUSU6JRWK=
LB373-MEL-D	NX\RNZNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTBwOEK1NFgh\|ryP	NFzpeIJUSU6JRWK=
TE-9	NX7VbWpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\rTWM2OD1yLki3OVMzKM7:TR?=	MV\TRW5ITVJ?
A3-KAW	MkTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDLTWM2OD1yLkm4OFUzKM7:TR?=	NXfC[3Z{W0GQR1XS
A101D	NXfYe2J4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{i5TmlEPTB;MT6wN\|A1OyEQvF2=	M3rSZnNCVkeHUh?=
OCUB-M	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHwTWM2OD1zLkC0OFEzKM7:TR?=	MVLTRW5ITVJ?
ES4	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{i3cmlEPTB;MT6wOVE1PSEQvF2=	M4XJWXNCVkeHUh?=
TE-6	NUX2WW9sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXjHbWhZUUN3ME2xMlIyOjJ4IN88US=>	MY\TRW5ITVJ?
D-502MG	NWTEeZptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfQNFhKSzVyPUGuNlM{PzZizszN	NWTuS2F1W0GQR1XS
KNS-42	NUHVcHY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfEZ2lvUUN3ME2xMlI1PDF{IN88US=>	NILrZ\|hUSU6JRWK=
SNU-C2B	NXS1WWhtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmL2TWM2OD1zLkOwOVg6KM7:TR?=	MlzlV2FPT0WU
NCI-H1838	NUXHTHJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHQdnFKSzVyPUGuN\|A4OzNizszN	MkDPV2FPT0WU
NKM-1	M1LnXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlHzTWM2OD1zLkOwPFU6KM7:TR?=	NHPFdWhUSU6JRWK=
GI-1	M3n6O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGL0cmxKSzVyPUGuN\|YzOiEQvF2=	NWrYPZNoW0GQR1XS
NB5	M{LvNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTFwM{m4Nlch\|ryP	M4HJSHNCVkeHUh?=
CAS-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTFwNEC5PVIh\|ryP	NGG1TZFUSU6JRWK=
HCE-T	M{TMXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGTGfmRKSzVyPUGuOVY4OTRizszN	NFKyXFRUSU6JRWK=
SBC-1	NFL2[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmCxTWM2OD1zLkW3PVg1KM7:TR?=	M1O5eHNCVkeHUh?=
JiyoyeP-2003	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTFwN{O0OlYh\|ryP	NX7JW\|lzW0GQR1XS
TE-5	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\VTWM2OD1zLke5NVM6KM7:TR?=	M3HScXNCVkeHUh?=
CAN	M1LxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGXPNGFKSzVyPUGuPFIzPTJizszN	MmP4V2FPT0WU
SK-UT-1	M37EO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTJwMU[2PVMh\|ryP	Mlz3V2FPT0WU
JVM-2	NFrHNJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\PTWM2OD1{LkO2Nlg1KM7:TR?=	NHTw[YZUSU6JRWK=
LB771-HNC	NED6WlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jSWWlEPTB;Mj61O\|U2OSEQvF2=	MnfRV2FPT0WU
NCCIT	MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fweGlEPTB;Mj64OlYyPiEQvF2=	Mk\JV2FPT0WU
NCI-H2126	M3vKVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nzVWlEPTB;Mj64O\|U2OiEQvF2=	NEHRT2pUSU6JRWK=
Calu-6	M{L1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTNwMEW3OFEh\|ryP	NGfhclJUSU6JRWK=
SK-LMS-1	NILJUFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTNwMUG4PFYh\|ryP	MXPTRW5ITVJ?
ARH-77	M1:4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTNwNE[5NVUh\|ryP	MVLTRW5ITVJ?
NB17	NV;NOYlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\JWY1KSzVyPUOuOlM5PDdizszN	MX3TRW5ITVJ?
A253	NVvoTYRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTNwN{OyOFYh\|ryP	NFHzeG5USU6JRWK=
OPM-2	MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGHZRlVKSzVyPUSuNlc3QDVizszN	NXrQcXpXW0GQR1XS
MV-4-11	M1TQUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXTSbmFVUUN3ME20MlM3PDV2IN88US=>	MnHjV2FPT0WU
SR	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4H5fmlEPTB;ND60PVk2PCEQvF2=	M1:1bXNCVkeHUh?=
KG-1	NY\wWZhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;UTWM2OD12Lk[wPFQ2KM7:TR?=	NFfVOnZUSU6JRWK=
OCI-AML2	Mmr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTVwOE[xOVQh\|ryP	NXzSeYp[W0GQR1XS
D-247MG	MnfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEm1dYJKSzVyPU[uNVI2OTlizszN	MWLTRW5ITVJ?
DJM-1	MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\YPVloUUN3ME22MlQ5PTV6IN88US=>	NIH4UGhUSU6JRWK=
RPMI-6666	NG\CcYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTdwMkewOlch\|ryP	NIjVNHpUSU6JRWK=
KARPAS-45	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTdwNUG2O\|Eh\|ryP	MUTTRW5ITVJ?
LP-1	NHjV[mhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWXnTWZzUUN3ME23MlU1Pzh{IN88US=>	MmnXV2FPT0WU
RS4-11	M{TRN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jrOmlEPTB;Nz62OVc5PyEQvF2=	Mme5V2FPT0WU
DU-4475	M{PHTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjuTWM2OD16LkKxOlUzKM7:TR?=	M1v0dnNCVkeHUh?=
MONO-MAC-6	NEi2WW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPmXldFUUN3ME24MlI4ODZ4IN88US=>	NFHuO5lUSU6JRWK=
NCI-SNU-16	M4\LUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3uwPGlEPTB;OD61OlEzQCEQvF2=	MUPTRW5ITVJ?
SJSA-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELoNm9KSzVyPUiuO\|I5ODVizszN	NVzEXFlyW0GQR1XS
MMAC-SF	MoHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRThwN{mzNFch\|ryP	MojzV2FPT0WU
SK-NEP-1	NXnIZZMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVr0U\|lJUUN3ME24Mlg6OTV3IN88US=>	M1fpbXNCVkeHUh?=
J-RT3-T3-5	NHLKcWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2TWOWlEPTB;OD65OlUzQSEQvF2=	MmG4V2FPT0WU
SKM-1	M4\3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWHvVlZmUUN3ME25MlAyPzN2IN88US=>	Mln3V2FPT0WU
LB2241-RCC	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{TES2lEPTB;OT6wNlAyOiEQvF2=	MWrTRW5ITVJ?
SIG-M5	M{C1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvPV2hKSzVyPUmuNFI1QTNizszN	NFnoenJUSU6JRWK=
EVSA-T	M3\ydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2O2dGlEPTB;OT6yO\|c6OyEQvF2=	NUXReGFNW0GQR1XS
GT3TKB	NU\iVm9GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVrMWHB7UUN3ME25MlM2PTR4IN88US=>	M{SwN3NCVkeHUh?=
NB6	M1v0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXv[ZB7UUN3ME25MlkzOjV7IN88US=>	MWLTRW5ITVJ?
EHEB	NWDaU2xpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2DjWmlEPTB;MUCuNFY2PiEQvF2=	NUSz[o5lW0GQR1XS
HEL	M4HzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoezTWM2OD1zMD60O\|c3KM7:TR?=	MnPqV2FPT0WU
ALL-PO	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXm[XFKSzVyPUGwMlc6OzhizszN	NGnCNVRUSU6JRWK=
TGW	MlnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3PTWM2OD1zMT6yPFI5KM7:TR?=	M13iO3NCVkeHUh?=
BC-3	NIDMbHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfkTIRKSzVyPUGyMlEyOzhizszN	MVvTRW5ITVJ?
IA-LM	MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2HhVGlEPTB;MUKuOFQ1PSEQvF2=	NGTycJpUSU6JRWK=
UACC-257	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;zNmlEPTB;MUKuPVE6QCEQvF2=	MWLTRW5ITVJ?
KP-N-YS	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUn1V\|Q3UUN3ME2xNk46Ojh\|IN88US=>	NHT6UGNUSU6JRWK=
Raji	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\FTWM2OD1zMz63OFk4KM7:TR?=	NHjHW4hUSU6JRWK=
SF539	NF\5VZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTF\|Lki1OVch\|ryP	MVfTRW5ITVJ?
DMS-153	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTF2LkCwNlgh\|ryP	NV7FTohFW0GQR1XS
L-540	MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEOxOFZKSzVyPUG1MlA3PzJizszN	M3H2[3NCVkeHUh?=
MN-60	NES1WnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTF3LkG5O\|kh\|ryP	NWD0WpdEW0GQR1XS
RPMI-8866	NVnSWIhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnL3TWM2OD1zNz60OFU1KM7:TR?=	NWjGS3hGW0GQR1XS
NCI-H510A	MonlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYHGTJlJUUN3ME2xPU4{QTd\|IN88US=>	NXv2UZFKW0GQR1XS
NB13	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn3vTWM2OD1zOT60PFc4KM7:TR?=	NGjWcGhUSU6JRWK=
HAL-01	MmfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2PZcWlEPTB;MUmuO\|U1OyEQvF2=	MojHV2FPT0WU
NCI-H720	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnI[pdKSzVyPUKwMlI4OzNizszN	MmPEV2FPT0WU
REH	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjnPGdPUUN3ME2yNE43OzV5IN88US=>	NF[5e\|NUSU6JRWK=
KNS-81-FD	Mme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVrEbI9ZUUN3ME2yN{4yPDZizszN	NH;ie4tUSU6JRWK=
HC-1	MnvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MU\JR\|UxRTJ2LkW1OVEh\|ryP	NYHOZVFQW0GQR1XS
NCI-H2141	MljTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3zMTGlEPTB;MkSuO\|c2PCEQvF2=	NGTYfnZUSU6JRWK=
MOLT-4	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY\xbnBwUUN3ME2yOk43PzV\|IN88US=>	M3jxUXNCVkeHUh?=
OMC-1	Ml64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPXTWM2OD1{Nz6xOFIzKM7:TR?=	NF7NO3VUSU6JRWK=
LC-1F	MkTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvJR\|UxRTJ5LkOyOFUh\|ryP	MVnTRW5ITVJ?
NCI-H1304	MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnnCTWM2OD1{OD6xOlI5KM7:TR?=	M3nF[HNCVkeHUh?=
BC-1	Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1;mOmlEPTB;MkiuOlUyKM7:TR?=	MkH3V2FPT0WU
NCI-H64	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4X1OWlEPTB;MkmuOlI2OyEQvF2=	MWXTRW5ITVJ?
MOLT-16	M1rUSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\ZdWlEPTB;MkmuOlI6OiEQvF2=	M4DicHNCVkeHUh?=
U-87-MG	NHLyT5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzJ[pB1UUN3ME2zNE44PjZizszN	M{P5SnNCVkeHUh?=
GAK	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2TZT2lEPTB;M{GuNlY5PiEQvF2=	MWfTRW5ITVJ?
ES8	M2KzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEDJTWZKSzVyPUOyMlEzPTJizszN	M2SxZnNCVkeHUh?=
HCC1599	M1zY[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTN{LkOzNlUh\|ryP	NU[5UWs5W0GQR1XS
EB-3	NGLRWJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGD1NHBKSzVyPUO0MlMyOTdizszN	MUDTRW5ITVJ?
HCC1187	NFnHPYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFPEWJpKSzVyPUO1MlgxPTJizszN	MoO5V2FPT0WU
SK-PN-DW	NWXBcmlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\tbZhKSzVyPUO2MlE6PDNizszN	M1uzS3NCVkeHUh?=
JVM-3	M4DiRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3HEe2lEPTB;M{euNlM{QCEQvF2=	MYrTRW5ITVJ?
HCC2157	Mn;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLVOZFKSzVyPUO3Mlk6PDZizszN	NILveXFUSU6JRWK=
A4-Fuk	NHGzPIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTN6LkGwNFkh\|ryP	MUDTRW5ITVJ?
COR-L279	MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvLcpVXUUN3ME20NE4zQDVzIN88US=>	NH\mR\|VUSU6JRWK=
DEL	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnPvTWM2OD12MT65NFg3KM7:TR?=	Ml7TV2FPT0WU
NCI-H1395	M1LWRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXruSopLUUN3ME20Nk4xOTZ\|IN88US=>	MmXBV2FPT0WU
MHH-NB-11	NV;ad2xvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;GTWM2OD12Mz6wPFE5KM7:TR?=	MnjXV2FPT0WU
NCI-H2107	M4LlWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MomwTWM2OD12Mz60PFQ3KM7:TR?=	M1LHd3NCVkeHUh?=
NEC8	M3HBS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPSPYhKSzVyPUS0MlM{PiEQvF2=	NWPYbm9MW0GQR1XS
COLO-684	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLSTWM2OD12Nj6yNlU5KM7:TR?=	NXTPOFlOW0GQR1XS
LS-411N	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLrTWM2OD12OD60O\|Q5KM7:TR?=	M1;EU3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416); PubMed: 23049975 PLoS One Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition. p27 / p21; PubMed: 20145167 Clin Cancer Res Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading. p-FAK / p-STAT3; PubMed: 23721490 BMC Cancer The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive. cleaved caspase 3; PubMed: 20145167 Clin Cancer Res Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control.	23049975 20145167 23721490
Growth inhibition assay	IC50; PubMed: 23721490 BMC Cancer 9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.	23721490
Immunofluorescence	SRC / Met; PubMed: 26517812 Oncotarget Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively. F-actin / Actinin-4 / Paxillin; PubMed: 31053734 Nat Commun Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions. α-tubulin; PubMed: 26517812 Oncotarget Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.	26517812 31053734
ELISA	TNF-α; PubMed: 17684099 Proc Natl Acad Sci U S A U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate. E-selectin; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM). VCAM-1; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM).	17684099 31110200

In vivo

Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. ^[3]

Protocol

Kinase Assay: ^[1]	- Collapse Kinase autophosphorylation assays: Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research: ^[1]	- Collapse Cell lines: Ba/F3 cell lines Concentrations: ~32 nM Incubation Time: 72 hours Method: Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I. (Only for Reference)
Animal Research: ^[3]	- Collapse Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC) Formulation: DMSO Dosages: 30 mg/kg Administration: Administered via i.p. (Only for Reference)

References

[4] Dargart JL, et al. Antiviral Res. 2012, 95(1), 49-56.

- Collapse

Solubility (25°C)

In vitro	DMSO	98 mg/mL (200.81 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dasatinib SDF

Molecular Weight	488.01
Formula	C₂₂H₂₆ClN₇O₂S
CAS No.	302962-49-8
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	BMS-354825

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04063124	Not yet recruiting	Drug: Dasatinib + Quercetin	Alzheimer Disease	The University of Texas Health Science Center at San Antonio\|Mayo Clinic	December 2019	Phase 1\|Phase 2
NCT04115059	Not yet recruiting	Drug: Dasatinib	Waldenstrom Macroglobulinemia\|DASATINIB	Jorge J. Castillo MD\|Bristol-Myers Squibb\|Dana-Farber Cancer Institute	November 2019	Phase 1
NCT03318770	Not yet recruiting	Drug: Dasatinib and blinatumomab	Acute Lymphoblastic Leukemia	Gruppo Italiano Malattie EMatologiche dell''Adulto	December 2018	--
NCT03625388	Recruiting	Drug: Dasatinib	Chronic Myelogenous Leukemia	Hikma Pharmaceuticals LLC	November 5 2018	Phase 2
NCT03193281	Recruiting	Drug: Dasatinib\|Drug: Imatinib	Chronic Myeloid Leukemia	University of Auckland New Zealand\|Leukaemia & Blood Cancer New Zealand	July 17 2017	Phase 2
NCT03041701	Recruiting	Drug: Dasatinib\|Drug: Ganitumab	Rhabdomyosarcoma\|Rhabdomyosarcoma- Alveolar\|Rhabdomyosarcoma-Embryonal	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	July 7 2017	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
what’s the difference between S1021 and S7782? Which one is better for in vivo studies?
Answer:
Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).
Question 2:
Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?
Answer:
Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Pan Src Inhibitor

Saracatinib (AZD0530) : Pan-Src inhibitor, IC50=2.7-11 nM for c-Src/c-Yes/Fyn/Lyn/Blk/Fgr/Lck.
FDA-approved Src Inhibitor

Bosutinib (SKI-606) : Approved by FDA for Ph+ chronic myelogenous leukemia (CML).
Newest Src Inhibitor

PP1 : Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
Classic Src Inhibitor

KX2-391 : The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

Related Src Products

Dasatinib Monohydrate ^New

Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.
SU6656 ^New

SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
PX-478 2HCl ^New

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.
Saracatinib (AZD0530)

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 2/3.

Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.
Bosutinib (SKI-606)

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.
KX2-391

KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.
PP1

PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
PP2

PP2, a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.
WH-4-023

WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50s of 2 nM and 6 nM in cell-free assays, respectively. Exhibits >300-fold selectivity against p38α and KDR. Also potently inhibits SIK (IC50 values are 10, 22 and 60 nM for SIK 1, 2 and 3 respectively) and displays selectivity over a range of closely related kinases.
Ibrutinib (PCI-32765)

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

Choose Your Country or Region

By Signaling Pathways

By product type

Dasatinib

Cited by 202 Publications

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Dasatinib SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Choose Your Country or Region

By Signaling Pathways

By product type

Dasatinib

Cited by 202 Publications

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Dasatinib SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)